EORTC/LinkedIn
Jul 29, 2025, 14:07
The results of the EORTC-1560-GITCG Multicentre Single-Arm Phase II Study – EORTC
European Organisation for Research and Treatment of Cancer (EORTC) shared a post on LinkedIn:
“New publication alert!
The results of the EORTC-1560-GITCG (ILOC) multicentre single-arm phase II study are now published in ESMO Open.
This study explored the combination of local ablative therapy combined with immunotherapy (durvalumab + tremelimumab) in patients with unresectable liver metastases from metastatic colorectal cancer.
The trial did not demonstrate anti-tumour activity of the combination in locally untreated liver colorectal metastases and emphasises the need to develop more effective immunotherapeutic strategies for metastatic colorectal cancer with liver involvement.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 25, 2025, 11:07
Aug 25, 2025, 09:45
Aug 25, 2025, 09:09
Aug 24, 2025, 21:47